The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 04, 2019
Filed:
Oct. 15, 2015
Syros Pharmaceuticals, Inc., Cambridge, MA (US);
Stephane Ciblat, Lachine, CA;
Anzhelika Kabro, Lachine, CA;
Melissa Leblanc, Laval, CA;
Serge Leger, Notre-Dame-De-1'ile-Perrot, CA;
Jason J. Marineau, Franklin, MA (US);
Tom Miller, Wakefield, MA (US);
Stephanie Roy, Lachine, CA;
Darby Schmidt, Arlington, MA (US);
Arshad M. Siddiqui, Newton, MA (US);
Kevin Sprott, Needham, MA (US);
Dana K. Winter, Rigaud, CA;
Amy Ripka, Reading, MA (US);
Dansu Li, Warrington, PA (US);
Guoli Zhang, Tianjin, CN;
Syros Pharmaceuticals, Inc., Cambridge, MA (US);
Abstract
The present invention provides novel compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase (e.g., CDK7), and therefore induce cellular apoptosis and/or inhibit transcription in the subject.